Challenges in treating older cancer patients: Colon cancer

Annals of Oncology

Volumn 19, Issue SUPPL. 7, 2008, Pages

  Papamichael, D ^a  

^a Bank of Cyprus Group Oncology Centre   (Cyprus)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CYTOTOXIC AGENT; FLUOROURACIL; FLUOROURACIL DERIVATIVE; FOLINIC ACID; IRINOTECAN; LEVAMISOLE; OXALIPLATIN; PANITUMUMAB; UFT;

ARTERY THROMBOSIS; BLEEDING DISORDER; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER STAGING; CLINICAL TRIAL; COLON CANCER; CONFERENCE PAPER; GERIATRIC PATIENT; HUMAN; HYPERTENSION; INTESTINE PERFORATION; LEUKOPENIA; LIVER METASTASIS; MONOTHERAPY; MUCOSA INFLAMMATION; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEINURIA; SURVIVAL TIME; THROMBOEMBOLISM; TREATMENT PLANNING; WOUND HEALING; ADJUVANT CHEMOTHERAPY; AGE; AGED; ARTICLE; COLON TUMOR; GERIATRICS; METASTASIS; METHODOLOGY; MIDDLE AGED; PATHOLOGY;

AGE FACTORS; AGED; AGED, 80 AND OVER; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; GERIATRICS; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING;

EID: 53449093123     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn463     Document Type: Conference Paper

References (68)

1. Aapro MS, Kohne CH, Cohen HJ, Extermann M. Never too old? Age should not be a barrier to enrollment in cancer clinical trials. Oncologist 2005; 10: 198-204.
2. Folprecht G, Cunningham D, Ross P et al. Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: A pooled analysis of clinical trials. Ann Oncol 2004; 15: 1330-1338.
3. Berrino F, Capoccaccia R, Esteve J, Gatta G. Survival of cancer patients in Europe: The EUROCARE-2 study. In Lyon: IARC 1999.
4. Biganzoli L, Aapro M. Adjuvant chemotherapy in the elderly. Ann Oncol 2003; 14 (Suppl, 3): Iii1-3.
5. Surbone A, Kagawa-Singer M, Terret C, Baider L. The illness trajectory of elderly cancer patients across cultures: SIOG position paper. Ann Onool 2007; 18: 633-638.
6. Andre T, Boni C, Mounedji-Boudiaf L et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343-2351.
7. Andre T, Tournigand C, Achille E et al. [Adjuvant treatment of colon cancer MOSAIC study's main results]. Bull Cancer 2006; 93 (Suppl. 1): S5-9.
8. Surgery for colorectal cancer in elderly patients: A systematic review: Colorectal Cancer Collaborative Group. Lancet 2000; 356: 968-974.
9. Neugut AI, Matasar M, Wang X, McBride R, Jacobson JS, Tsai WY. Duration of adjuvant chemotherapy for colon cancer and survival among the elderly. J Clin Oncol 2006; 24: 2368-2375.
10. Potosky AL, Harlan LC, Kaplan RS et al. Age, sex, and racial differences in the use of standard adjuvant therapy for colorectal cancer. J Clin Oncol 2002; 20: 1192-1202.
11. Schrag D, Cramer LD, Bach PB, Begg CB. Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst 2001; 93: 850-857.
12. Sundararajan V, Mitra N, Jacobson JS et al. Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer. Ann Intern Med 2002; 136: 349-357.
13. Hutchins LF, Unger JM, Crowley JJ et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999; 341: 2061-2067.
14. Sargent DJ, Goldberg RM, Jacobson SD et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 2001; 345: 1091-1097.
15. Jessup JM, Stewart A, Greene FL, Minsky BD. Adjuvant chemotherapy for stage III colon cancer: Implications of race/ethnicity, age, and differentiation. JAMA 2005; 294: 2703-2711.
16. Scheithauer W, McKendrick J, Begbie S et al. Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: Safety results of a randomized, phase III trial. Ann Oncol 2003; 14: 1735-1743.
17. Poole C, Gardiner J, Twelves C et al. Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients. Cancer Chemother Pharmacol 2002; 49: 225-234.
18. Twelves C, Scheithauer W, MacKendrik M et al. Capecitabine versus 5-FU/ LV in stage III colon cancer: Updated 5-year efficacy data from X-ACT trial and preliminary analysis of relationship between hand-foot syndrome (HFS) and efficacy. Proceedings ASCO Gastrointestinal Cancers Symposium www.asco.org 2008; (abstract 274).
19. Lembersky BC, Wieand HS, Petrelli NJ et al. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: Results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol 2006; 24: 2059-2064.
20. Popescu RA, Norman A, Ross PJ et al. Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J Clin Oncol 1999; 17: 2412-2418.
21. Goldberg RM, Tabah-Fisch I, Bleiberg H et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 2006; 24: 4085-4091.
22. Quasar Collaborative Group. Adjuvant chemotherapy versus observation in patients with colorectal cancer: A randomised study. Lancet 2007; 370: 2020-2029.
23. Beretta G, Bollina R, Cozzi C, Beretta G. Should we consider weekly (w) chemotherapy with 5-fluorouracil (F) + racemic folinic acid (f) a standard treatment for carcinoma of the digestive tract (DTD) in elderly patients. Proc Am Soc Clin Oncol 1997: (Abstract 920).
24. Mitry E, Douillard JY, Van Cutsem E et al. Predictive factors of survival in patients with advanced colorectal cancer: An individual data analysis of 602 patients included in irinotecan phase III trials. Ann Oncol 2004; 15: 1013-1017.
25. Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 2000; 355: 1041-1047.
26. Kohne CH, van Cutsem E, Wils J et al. Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J Clin Oncol 2005; 23: 4856-4865.
27. Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343: 905-914.
28. Folprecht G, Rougier P, Saltz L et al. Irinotecan in first line therapy of elderly and non-elderly patients with metastatic colorectal cancer: meta-analysis of four trials investigating 5-FU and irinotecan. J Clin Oncol 2006; 24(18S): (Abstract 3578).
29. Goldberg RM, Sargent DJ, Morton RF et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22: 23-30.
30. de Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-2947.
31. Rothenberg ML, Oza AM, Bigelow RH et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: Interim results of a phase III trial. J Clin Oncol 2003; 21: 2059-2069.
32. Rosati G, Cordio S, Tucci A et al. Phase II trial of oxaliplatin and tegafur/uracil and oral folinic acid for advanced or metastatic colorectal cancer in elderly patients. Oncology 2005; 69: 122-129.
33. Sastre J, Marcuello E, Masutti B et al. Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: A Spanish Cooperative Group for the Treatment of Digestive Tumors study. J Clin Oncol 2005; 23: 3545-3551.
34. Twelves CJ, Butts CA, Cassidy J et al. Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: Post hoc analysis of a large phase II study. Clin Colorectal Cancer 2005; 5: 101-107.
35. Seymour MT, Maughan TS, Wasan HS et al. Capecitabine (Cap) and oxaliplatin (Ox) in elderly and/or frail patients with metastatic colorectal cancer: The FOCUS2 trial. J Clin Oncol 2007: (Abstract 9030).
36. Mitry E, Phelip JM, Bonnetain F et al. Phase III trial of chemotherapy with or without irinotecan in the front-line treatment of metastatic colorectal cancer in elderly patients (FFCD 2001-02 trial): Results of a planned interim analysis. ASCO Gastrointestinal Cancers Symposium www.asco.org 2008: (Abstract 281).
37. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-345.
38. Saltz LB, Meropol NJ, Loehrer PJ Sr et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22: 1201-1208.
39. Kabbinavar F, Hurwitz HI, Fehrenbacher L et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21: 60-65.
40. Kabbinavar FF, Hambleton J, Mass RD et al. Combined analysis of efficacy: The addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005; 23: 3706-3712.
41. Lenz HJ, Mayer RJ, Mirtsching B et al. Consistent response to treatment with cetuximab monotherapy in patients with metastatic colorectal cancer. J Clin Oncol 2005; 23(16S): (Abstract 3536).
42. Pessino A, Artale S, Guglielmi A et al. First-line single-agent cetuximab in patients with advanced colorectal cancer. J Clin Oncol 2006; 24(18S): (Abstract 3553).
43. Saltz L, Meropol NJ, Loehrer PJ et al. Single agent IMC-C225 (ErbituxTM) has activity in CPT-11-refractory colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 2002: 21 (Abstract 504).
44. Sastre J, Aranda E, Gravalos C et al. Single-agent cetuximab as first-line treatment for elderly patients with advanced colorectal cancer: Preliminary results of a TTD phase II study. Ann Oncol 2006; 17 (Suppl 9): (Abstract 3240).
45. Humblet Y, Van Cutsem E, Peeters M. Panitumumab for the treatment of metastatic colorectal Cancer (MCRC): A multicenter study in patients (pts) who failed chemotherapy (CTX) and best supportive care (BSC). Ann Oncol 2006; 17 (Suppl 9): (Abstract 3250).
46. Giacchetti S, Itzhaki M, Gruia G et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 1999; 10: 663-669.
47. Tournigand C, Andre T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 2004; 22: 229-237.
48. Folprecht G, Grothey A, Alberts S et al. Neoadjuvant treatment of unresectable colorectal liver metastases: Correlation between tumour response and resection rates. Ann Oncol 2005; 16: 1311-1319.
49. Bismuth H, Adam R, Levi F et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996; 224: 509-520.
50. Adam R. Chemotherapy and surgery: New perspectives on the treatment of unresectable liver metastases. Ann Oncol 2003; 14 (Suppl. 2): Ii13-6.
51. Cervantes A, Casado E, Van Cutsem E et al. Cetuximab plus oxaliplatin/ 5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) for the epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer (mCRC) in the first-line setting: A phase II study. Eur J Cancer Suppl 2005; 3: 181 (Abstract 642).
52. Fisher GA, Kuo T, Cho D et al. A phase II study of gefitinib in combination with FOLFOX-4 (IFOX) in patients with metastatic colorectal cancer. J Clin Oncol 2004; 22(14S): (Abstract 3514).
53. Folprecht G, Lutz MP, Schoffski P et al. Cetuximab and irinotecan/ 5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol 2006; 17: 450-456.
54. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
55. Kopetz S, Abbruzzese JL, Eng C et al. Preliminary results from a phase II study of infusional 5-FU, leucovorin and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancer (mCRC). J Clin Oncol 2006; 24(18S): (Abstract 3579).
56. Peeters M, Raoul J-L, Van Laetham J-L et al. Cetuximab in combination with irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFIRI) in the first-line treatment of metastatic colorectal cancer. Eur J Cancer Suppl 2005; 3: 188 (Abstract 664).
57. Abad A, Anton A, Massuti B et al. Resectability of liver metastases (LM) in patients with advanced colorectal cancer (ACRC) after treatment with the combination of oxaliplatin (OXA), irinotecan (IRI) and 5-FU: Final results of a phase II study. J Clin Oncol 2005; 23: 275 (Abstract 3618).
58. Falcone A, Masi G, Murr R et al. Biweekly irinotecan, oxaliplatin, and infusional 5-FU/LV (FOLFOXIRI) versus FOLFIRI as first-line treatment of metastatic CRC (MCRC). ASCO Gastrointestinal Cancers Symposium www.asco.org 2006: (Abstract 227).
59. Quenet F, Nordlinger B, Rivoire M et al. Resection of previously unresectable liver metastases from colorectal cancer after chemotherapy with CPT-11/L-OHP/LV5FU (Folfirinox): A prospective phase II trial. Proc Am Soc Clin Oncol 2004: 23 (Abstract 3613).
60. Seium Y, Stupp R, Ruhstaller T et al. Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: A phase I-II study. Ann Oncol 2005; 16: 762-766.
61. Karoui M, Penna C, Amin-Hashem M et al. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg 2006; 243: 1-7.
62. Vauthey JN, Pawlik TM, Ribero D et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006; 24: 2065-2072.
63. Adam R, Laurent C, Poston G et al. Liver resection of colorectal metastases in elderly patients: Is it worthwhile and is there an age limit? Proc ASCO GI 2008; (Abstract 452).
64. Trimble EL, Christian MC. Cancer treatment and the older patient. Clin Cancer Res 2006; 12(7 Pt 1): 1956-1957.
65. Muss HB, Biganzoli L, Sargent DJ, Aapro M. Adjuvant therapy in the elderly: Making the right decision. J Clin Oncol 2007; 25: 1870-1875.
66. Sanoff HK, Bleiberg H, Goldberg RM. Managing older patients with colorectal cancer. J Clin Oncol 2007; 25: 1891-1897.
67. Giantonio BJ, Catalano PJ, Meropol NJ et al. High-dose bevacizumab in combination with FOLFOX4 improves survival in patients with previously treated advanced colorectal cancer: Results of the Eastern Co-operative Oncology Group. ASCO Gastrointestinal Cancers Symposium www.asco.org 2005: (Abstract 169a).
68. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.